Pharmacyclics submits filing for cancer drug

On the basis of results from the Phase 3 RESONATE clinical trial, Pharmacyclics (PCYC) files a supplemental NDA for its oral kinase inhibitor IMBRUVICA as a single therapeutic agent for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior therapy.

The trial compared IMBRUVICA (ibrutinib) to ofatumumab in 391 patients. Patients treated with IMBRUVICA alone showed a statistically significant improvement in the secondary endpoint of overall survival.

The FDA granted accelerated approval status for the product as a single agent for the treatment of the cancers cited above.

The company's development and commercialization partner is Janssen Biotech (JNJ).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs